Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03535883 · ClinicalTrials.gov registry record
The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 590
- Enrollment target
NCT03535883: Completed study, sponsored by Yale University.
NCT03535883 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 590 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03535883 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 590 participants
- Enrollment target
Study Summary
To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC) medications, admitted to the hospital and require thoracentesis, chest tube or tunneled pleural catheter placement.
Primary Outcome
Reduced risk of bleeding in individuals receiving Novel Oral Anti-Coagulants as well as those that are in the control group will be assessed by having the patients undergo an analysis of their pre-procedural hematocrit which will be compared to their post procedural (next day) hematocrit
Interventions
- DRUG Novel Oral Anti-Coagulants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2017-10-30 |
| Est. Completion | 2020-01-01 |
What the finished NCT03535883 record still lists
NCT03535883 is an observational study that tracks outcomes without assigning an intervention. The registered 590 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Novel Oral Anti-Coagulants is the first listed.
NCT03535883 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03535883 about?
NCT03535883 is a clinical study titled "The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants". To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC) medications, admitted to the hospital and require thoracentesis, chest tube or tunneled pleural catheter placement.
What is the current status of trial NCT03535883?
This trial is currently completed. The enrollment target is 590 participants. The study started on 2017-10-30. Estimated completion is 2020-01-01.
What interventions are being tested in trial NCT03535883?
The interventions under investigation include: Novel Oral Anti-Coagulants (DRUG).
Who is sponsoring clinical trial NCT03535883?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
- NCT04747626 · 590 participants · NA
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
- NCT05722938 · 590 participants · Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI